Companies
/
Ro
Healthtech
Ro is a New York-based direct-to-consumer telehealth company offering virtual care and medication delivery across primary care, weight management, and men's and women's health, notably for GLP-1 weight-loss treatments.
$2.92B
+$5.99
1,505.80%
30 days ago
$0.40
Create an account to view live offerings, pricing, and market activity.
Sign in to view offerings and live market activity.
Sign up with Augment to see the latest market activity.
Ro was founded in 2017 by Zachariah Reitano, Saman Rahmanian, and Rob Schutz under the earlier brand name Roman, initially focused specifically on men's health conditions such as erectile dysfunction and hair loss, categories that many men found embarrassing to discuss with a traditional in-person doctor, making a discreet, entirely virtual telehealth service particularly appealing for these specific conditions, before the company expanded its scope significantly beyond its original men's health focus into broader primary care, women's health under a companion brand called Rory, and, increasingly, weight management services centered on prescribing and managing GLP-1 receptor agonist medications such as Wegovy and Zepbound that have become enormously popular and commercially significant for weight loss. Ro's platform lets patients complete an online medical intake, consult virtually with a licensed healthcare provider, and, when clinically appropriate, receive a prescription that can be filled and delivered directly to their home through Ro's own affiliated pharmacy operations, an integrated model spanning the full patient journey from initial consultation through medication delivery that the company has argued provides a more convenient, coordinated experience than patients navigating separate doctor visits and pharmacy pickups through traditional in-person healthcare channels. The company's expansion into GLP-1 weight-loss medication management has become an increasingly significant part of its business given the extraordinary consumer demand for these medications, positioning Ro to compete with numerous other telehealth companies and traditional healthcare providers all seeking to capture demand for GLP-1 prescribing and ongoing patient management as these medications have reshaped the weight management and broader healthcare landscape. Ro has navigated the broader regulatory and reputational scrutiny that has affected the telehealth prescribing industry more broadly, particularly regarding appropriate clinical oversight for medications requiring careful patient monitoring. The company has raised very substantial venture funding from investors including General Catalyst, Founders Fund, and TQ Ventures, reaching a valuation exceeding $7 billion at its peak, competing with other direct-to-consumer telehealth platforms including Hims & Hers in the fast-growing telehealth and weight management medication category.
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
